Home LiteratureArticle Details
PMID: 18493227 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

The prevention of type 2 diabetes.

Nature clinical practice. Endocrinology & metabolism ·Vol. 4 ·No. 7 ·2008-07-00 ·Pages 382-93

Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM, Diabetes Prevention Program Research Group

Abstract

Type 2 diabetes mellitus (T2DM) affects more than 7% of adults in the US and leads to substantial personal and economic burden. In prediabetic states insulin secretion and action--potential targets of preventive interventions--are impaired. In trials lifestyle modification (i.e. weight loss and exercise) has proven effective in preventing incident T2DM in high-risk groups, although weight loss has the greatest effect. Various medications (e.g. metformin, thiazolidinediones and acarbose) can also prevent or delay T2DM. Whether diabetes-prevention strategies also ultimately prevent the development of diabetic vascular complications is unknown, but cardiovascular risk factors are favorably affected. Preventive strategies that can be implemented in routine clinical settings have been developed and evaluated. Widespread application has, however, been limited by local financial considerations, even though cost-effectiveness might be achieved at the population level.

MeSH Terms
Diabetes Mellitus, Type 2/prevention & control Humans Hypoglycemic Agents/therapeutic use Life Style Prediabetic State/drug therapy,therapy
Chemicals
Hypoglycemic Agents
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Crandall Jill P
Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA. [email protected]
Knowler William C
Kahn Steven E
Marrero David
Florez Jose C
Bray George A
Haffner Steven M
Hoskin Mary
Nathan David M
Diabetes Prevention Program Research Group
References (92)
92 references, click to expand
  1. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
    Curr Med Res Opin. 2007 Apr;23(4):933-44 PMID: 17407650
  2. Prevention or delay of type 2 diabetes.
    Diabetes Care. 2004 Jan;27 Suppl 1:S47-54 PMID: 14693925
  3. A pilot urban church-based programme to reduce risk factors for diabetes among Western Samoans in New Zealand.
    Diabet Med. 1998 Feb;15(2):136-42 PMID: 9507914
  4. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
    Lancet. 2006 Sep 23;368(9541):1096-105 PMID: 16997664
  5. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
    N Engl J Med. 2001 May 3;344(18):1343-50 PMID: 11333990
  6. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.
    Diabetes Care. 1997 Apr;20(4):537-44 PMID: 9096977
  7. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
    Diabetes Care. 2003 Oct;26(10):2713-21 PMID: 14514569
  8. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
    J Clin Invest. 1999 Sep;104(6):787-94 PMID: 10491414
  9. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP).
    Diabetes Care. 2007 Oct;30(10):2548-52 PMID: 17670917
  10. Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study.
    J Clin Endocrinol Metab. 2004 Dec;89(12):6286-90 PMID: 15579791
  11. Community-based lifestyle interventions to prevent type 2 diabetes.
    Diabetes Care. 2003 Sep;26(9):2643-52 PMID: 12941733
  12. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.
    Arch Intern Med. 2007 May 28;167(10):1068-74 PMID: 17533210
  13. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    JAMA. 2003 Jul 23;290(4):486-94 PMID: 12876091
  14. Bienestar: a diabetes risk-factor prevention program.
    J Sch Health. 1998 Feb;68(2):62-7 PMID: 9571575
  15. Effect of ramipril on the incidence of diabetes.
    N Engl J Med. 2006 Oct 12;355(15):1551-62 PMID: 16980380
  16. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
    J Clin Endocrinol Metab. 2007 Apr;92(4):1502-9 PMID: 17213274
  17. Effectiveness of community-directed diabetes prevention and control in a rural Aboriginal population in British Columbia, Canada.
    Soc Sci Med. 1999 Mar;48(6):815-32 PMID: 10190643
  18. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?
    Ann Intern Med. 2002 Apr 16;136(8):575-81 PMID: 11955025
  19. Effect of weight loss with lifestyle intervention on risk of diabetes.
    Diabetes Care. 2006 Sep;29(9):2102-7 PMID: 16936160
  20. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Ann Intern Med. 2005 Aug 16;143(4):251-64 PMID: 16103469
  21. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.
    JAMA. 2008 Jan 23;299(3):316-23 PMID: 18212316
  22. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up.
    Am J Clin Nutr. 1992 Feb;55(2 Suppl):582S-585S PMID: 1733132
  23. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
    N Engl J Med. 2005 Dec 22;353(25):2643-53 PMID: 16371630
  24. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
    Diabetes Care. 2005 Apr;28(4):888-94 PMID: 15793191
  25. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.
    Diabetes Care. 2000 Nov;23(11):1619-29 PMID: 11092283
  26. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.
    Ann Intern Med. 2007 Mar 20;146(6):461-3 PMID: 17371892
  27. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.
    Diabetes. 2005 May;54(5):1566-72 PMID: 15855347
  28. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study.
    J Clin Endocrinol Metab. 2005 Feb;90(2):813-9 PMID: 15585553
  29. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
    Circulation. 2001 Jan 23;103(3):357-62 PMID: 11157685
  30. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    N Engl J Med. 2006 Dec 7;355(23):2427-43 PMID: 17145742
  31. Trying to predict the future for people with diabetes: a tough but important task.
    Ann Intern Med. 2005 Aug 16;143(4):301-2 PMID: 16103474
  32. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.
    Lancet. 2006 Nov 11;368(9548):1673-9 PMID: 17098085
  33. Genetic prediction of future type 2 diabetes.
    PLoS Med. 2005 Nov 1;2(12):e345 PMID: 17570749
  34. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program.
    Diabetes Care. 2006 Apr;29(4):914-9 PMID: 16567837
  35. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
    Lancet. 2002 Jun 15;359(9323):2072-7 PMID: 12086760
  36. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism.
    Ann Surg. 2004 Aug;240(2):236-42 PMID: 15273546
  37. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.
    Diabetes. 2002 Jul;51(7):2170-8 PMID: 12086947
  38. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes.
    Diabetologia. 1982 Feb;22(2):73-8 PMID: 7060852
  39. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.
    Diabetes. 1980 Jan;29(1):41-9 PMID: 7380107
  40. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program.
    Diabetes Care. 2006 Sep;29(9):1997-2002 PMID: 16936143
  41. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.
    Diabetes. 2007 Feb;56(2):531-6 PMID: 17259403
  42. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
    Arch Intern Med. 2000 May 8;160(9):1321-6 PMID: 10809036
  43. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.
    J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1075-81 PMID: 17077202
  44. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).
    Diabetologia. 2006 Feb;49(2):289-97 PMID: 16391903
  45. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.
    Diabetes Care. 2003 Apr;26(4):977-80 PMID: 12663559
  46. Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review.
    Pharmacoeconomics. 2006;24(5):425-41 PMID: 16706569
  47. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.
    N Engl J Med. 2006 Jul 20;355(3):241-50 PMID: 16855264
  48. Randomized clinical trial of lifestyle interventions in Pima Indians: a pilot study.
    Diabet Med. 1998 Jan;15(1):66-72 PMID: 9472866
  49. Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function.
    Diabetologia. 2006 Sep;49(9):2136-43 PMID: 16819611
  50. Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes").
    Diabetologia. 1979 Jan;16(1):25-30 PMID: 761734
  51. A pilot diabetes awareness and exercise programme in a multiethnic workforce.
    N Z Med J. 1996 Oct 11;109(1031):373-6 PMID: 8890876
  52. A project to reduce the burden of diabetes in the African-American Community: Project DIRECT.
    J Natl Med Assoc. 1998 Oct;90(10):605-13 PMID: 9803725
  53. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
    Lancet. 2003 Jun 14;361(9374):2005-16 PMID: 12814710
  54. Preventing non-insulin-dependent diabetes.
    Diabetes. 1995 May;44(5):483-8 PMID: 7729603
  55. Evaluation of Jump Into Action: a program to reduce the risk of non-insulin dependent diabetes mellitus in school children on the Texas-Mexico border.
    J Sch Health. 1998 Sep;68(7):282-8 PMID: 9779403
  56. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Drugs. 2004;64 Suppl 2:43-60 PMID: 15765890
  57. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    N Engl J Med. 2007 Jun 14;356(24):2457-71 PMID: 17517853
  58. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
    Ann Intern Med. 2005 Apr 19;142(8):611-9 PMID: 15838067
  59. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
    Diabetes Care. 2004 Jan;27(1):155-61 PMID: 14693982
  60. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
    Diabetes. 2005 Apr;54(4):1150-6 PMID: 15793255
  61. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study.
    Diabetes. 2005 Jan;54(1):158-65 PMID: 15616024
  62. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.
    Ann Surg. 1995 Sep;222(3):339-50; discussion 350-2 PMID: 7677463
  63. Standards of medical care in diabetes--2008.
    Diabetes Care. 2008 Jan;31 Suppl 1:S12-54 PMID: 18165335
  64. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
    Diabetes. 2005 Aug;54(8):2404-14 PMID: 16046308
  65. Reduced prevalence of impaired glucose tolerance and no change in prevalence of diabetes despite increasing BMI among Aboriginal people from a group of remote homeland communities.
    Diabetes Care. 2000 Jul;23(7):898-904 PMID: 10895838
  66. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.
    BMJ. 2007 Feb 10;334(7588):299 PMID: 17237299
  67. National type 2 diabetes prevention programme in Finland: FIN-D2D.
    Int J Circumpolar Health. 2007 Apr;66(2):101-12 PMID: 17515250
  68. STOP diabetes! An educational model for Native American adolescents in the prevention of diabetes.
    Diabetes Educ. 1998 Jul-Aug;24(4):441-3, 446-50 PMID: 9830948
  69. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
    N Engl J Med. 2004 Dec 23;351(26):2683-93 PMID: 15616203
  70. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.
    Diabetologia. 2005 Nov;48(11):2248-53 PMID: 16205886
  71. Prevention of type 2 diabetes in childhood.
    Clin Pediatr (Phila). 1998 Feb;37(2):123-9 PMID: 9492121
  72. Development of a primary prevention program: insight gained in the Zuni Diabetes Prevention Program.
    Clin Pediatr (Phila). 1998 Feb;37(2):131-41 PMID: 9492122
  73. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Ann Intern Med. 2005 Mar 1;142(5):323-32 PMID: 15738451
  74. Impaired fasting glucose and impaired glucose tolerance: implications for care.
    Diabetes Care. 2007 Mar;30(3):753-9 PMID: 17327355
  75. Ramipril and the development of diabetes.
    JAMA. 2001 Oct 17;286(15):1882-5 PMID: 11597291
  76. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance.
    Diabetes Res Clin Pract. 2003 Sep;61(3):183-90 PMID: 12965108
  77. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.
    Diabetes Res Clin Pract. 2005 Feb;67(2):152-62 PMID: 15649575
  78. Glucose tolerance and mortality, including a substudy of tolbutamide treatment.
    Diabetologia. 1997 Jun;40(6):680-6 PMID: 9222648
  79. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
    N Engl J Med. 2002 Feb 7;346(6):393-403 PMID: 11832527
  80. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion.
    Diabetologia. 2007 Jun;50(6):1192-200 PMID: 17437080
  81. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study.
    Diabetes Care. 1994 May;17(5):372-5 PMID: 8062602
  82. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program.
    Diabetes. 2007 Apr;56(4):1153-9 PMID: 17395752
  83. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.
    Diabetologia. 2003 Jan;46(1):3-19 PMID: 12637977
  84. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
    Diabetes. 2002 Sep;51(9):2796-803 PMID: 12196473
  85. Effect of a multifactorial intervention on mortality in type 2 diabetes.
    N Engl J Med. 2008 Feb 7;358(6):580-91 PMID: 18256393
  86. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
    Diabetes Care. 1999 Apr;22(4):623-34 PMID: 10189543
  87. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies.
    Diabetes. 1997 Apr;46(4):701-10 PMID: 9075814
  88. Long-term non-pharmacological weight loss interventions for adults with prediabetes.
    Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005270 PMID: 15846748
  89. Walking campaign: a model for developing participation in physical activity? Experiences from three campaign periods of the Stockholm Diabetes Prevention Program (SDPP).
    Patient Educ Couns. 2001 Jan;42(1):9-14 PMID: 11080601
  90. Mediators of lifestyle behavior change in Native Hawaiians: initial findings from the Native Hawaiian Diabetes Intervention Program.
    Diabetes Care. 2001 Oct;24(10):1770-5 PMID: 11574440
  91. Is type II diabetes mellitus (NIDDM) a surgical disease?
    Ann Surg. 1992 Jun;215(6):633-42; discussion 643 PMID: 1632685
  92. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model.
    Diabetes Educ. 2007 Jan-Feb;33(1):69, 74-5, 77-8 PMID: 17272794
Article Info
Journal
Nature clinical practice. Endocrinology & metabolism
Abbr.
Nat Clin Pract Endocrinol Metab
ISSN
1745-8374
DOI
10.1038/ncpendmet0843
Email
[email protected]
Published
2008-07-00
Epub
2008-00-20
Pages
382-93
Language
English
Region
England
NLM ID
101261798
PMCID
PMC2573045
Subset
IM
Grants
NIDDK NIH HHS · U01 DK048489 · United States
NIDDK NIH HHS · U01 DK048489-06 · United States
Intramural NIH HHS · Z01 DK069000-42 · United States
External Links
PubMed source DOI: 10.1038/ncpendmet0843 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2